Irinotecan with or without capecitabine as a beyond 2nd line regime for esophago-gastric adenocarcinomas.
Volume: 38, Issue: 15_suppl, Pages: e16545 - e16545
Published: May 20, 2020
Abstract
e16545 Background: Purpose: The aim of this retrospective study was to assess the efficacy and toxicity of irinotecan +/- capecitabine for patients with metastatic esophago-gastric (EG) adenocarcinomas previously treated with at least two chemotherapy regimens including platinum-based, fluoropyramidines and taxanes. Introduction: Treatment for metastatic EG cancer beyond 2 nd line remains controversial. Recently, the TAGS phase III trial...
Paper Details
Title
Irinotecan with or without capecitabine as a beyond 2nd line regime for esophago-gastric adenocarcinomas.
Published Date
May 20, 2020
Journal
Volume
38
Issue
15_suppl
Pages
e16545 - e16545
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History